Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040743 | 0.94 | DGAT1 (0.49) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL14158944 | 0.90 | ALDH1A1 (0.57) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL3523655 | 0.86 | TDP1 (0.60) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL1467340 | 0.85 | NAAA (0.56) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL24920365 | 0.84 | ALDH1A1 (0.51) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL17623638 | 0.84 | ESRRG (0.57) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL17623630 | 0.84 | L3MBTL1 (0.57) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL17623598 | 0.84 | ALDH1A1 (0.51) | TDP1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL22767691 | 0.83 | TDP1 (0.56) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL20649129 | 0.83 | NPC1 (0.58) | TDP1MEN1GAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | TDP1 1814/4885MEN1 829/4885GAA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.